ALX ONCOLOGY HOLDINGS INC 8-K

What Happened

• On January 30, 2026, ALX Oncology Holdings Inc. filed a Form 8-K and issued a press release with new topline data from a Phase 1b/2 trial of its investigational CD47 inhibitor evorpacept combined with Jazz Pharmaceuticals’ ZIIHERA® (zanidatamab-hrii) in heavily pretreated metastatic breast cancer (mBC) patients. An exploratory analysis reported that, among patients with confirmed HER2‑positive mBC, CD47 expression was predictive of evorpacept activity.
• The company also disclosed a preliminary, unaudited estimate of approximately $48.3 million in cash and cash equivalents and short‑term and long‑term investments as of December 31, 2025. The year‑end close is not complete and the figure is subject to change; the independent auditor has not reviewed or audited this estimate.

Key Details

• Press release and topline clinical findings dated January 30, 2026 (filed as Exhibit 99.1 to the 8‑K).
• Trial: Phase 1b/2 combination of evorpacept with zanidatamab in heavily pretreated metastatic breast cancer.
• Clinical result: Exploratory analysis indicates CD47 expression predicted evorpacept activity in confirmed HER2‑positive mBC patients (topline/exploratory finding).
• Preliminary liquidity: ~$48.3 million in cash and short‑/long‑term investments as of 12/31/2025; unaudited and subject to change pending year‑end close.

Why It Matters

• Clinical: The signal that CD47 expression may predict response could guide patient selection and future development plans for evorpacept in HER2‑positive mBC. These are early, exploratory topline results — useful as a directional data point but not definitive.
• Financial: The $48.3M preliminary cash/investment estimate gives investors an initial view of ALX’s liquidity at year‑end, but it is unaudited and incomplete. Investors should await the completed year‑end financial statements for final cash position, revenue/expense details, and any implications for runway or financing needs.